Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).

被引：2
|
作者：
O'Leary-Kelly, Meghan
Gao, Dexiang
Weisdack, Sarah
Lam, Elaine Tat
Bernard, Brandon David
Flaig, Thomas W.
Kessler, Elizabeth Riley
机构：
[1] Univ Colorado Canc Ctr, Aurora, CO USA
[2] Univ Colorado Denver, Aurora, CO USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[4] Univ Colorado Comprehens Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.331
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [32] Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Mar, Nataliya
    Dwabe, Sami
    Baranda, Marlon N.
    Zarrabi, Kevin K.
    Eturi, Aditya
    Gulati, Shuchi
    Parikh, Mamta
    Seyedin, Steven N.
    Kalebasty, Arash Rezazadeh
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 217 - 223
  • [33] The use of intermittent enzalutamide dosing in the treatment of metastatic castrate-resistant prostate cancer
    Rowe, Michael
    Hidayat, Ayesha
    Walter, Stuart
    Pollard, Adam
    Norris, Timothy
    Victor, Deborah
    McGrane, John
    Thomson, Alastair
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Use of bone modifying agents for metastatic castrate-resistant prostate cancer.
    Mitchell, Aaron Philip
    Meza, Akriti Mishra
    Farooki, Azeez
    Panageas, Katherine
    Bach, Peter B.
    Lipitz-Snyderman, Allison
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
    Marar, Mallika
    Long Qi
    Mamtani, Ronac
    Narayan, Vivek
    Vapiwala, Neha
    Parikh, Ravi Bharat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [36] Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.
    Shepard, D. R.
    Weil, A.
    Garcia, J. A.
    Dreicer, R.
    Raghavan, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Prognostic utility of FDG PET/CT in men with castrate-resistant metastatic prostate cancer
    Jadvar, Hossein
    Desai, Bhushan
    Ji, Lingyun
    Conti, Peter
    Dorff, Tanya
    Pinski, Jacek
    Quinn, David
    Groshen, Susan
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [38] Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer
    Iacovelli, R.
    Ciccarese, C.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1192 - 1193
  • [39] Pain Response to Radium-223 in Men With Metastatic Castrate-Resistant Prostate Cancer
    Zhang, I.
    Gilbo, P.
    Cox, B. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E530 - E530
  • [40] The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC)
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Hansen, Aaron Richard
    Joshua, Anthony M.
    Warde, Padraig Richard
    Gregg, Richard William
    Fleshner, Neil Eric
    Tomlinson, George
    Hotte, Sebastien J.
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345